The normal haematocrit trial in patients with cardiac disease: are we any the less confused about target haemoglobin?

Medicine is the science of probability, and the art of positive benefit not be achieved even if the study were allowed to continue, but more concerningly the interim uncertainty-Sir William Osler results suggested there may be a borderline higher mortality in the group of patients aiming for a normal